ATE352319T1 - Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor - Google Patents

Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor

Info

Publication number
ATE352319T1
ATE352319T1 AT02787572T AT02787572T ATE352319T1 AT E352319 T1 ATE352319 T1 AT E352319T1 AT 02787572 T AT02787572 T AT 02787572T AT 02787572 T AT02787572 T AT 02787572T AT E352319 T1 ATE352319 T1 AT E352319T1
Authority
AT
Austria
Prior art keywords
inhibitor
combination
cyclooxygenase
histone deacetylase
relates
Prior art date
Application number
AT02787572T
Other languages
English (en)
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE352319T1 publication Critical patent/ATE352319T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02787572T 2001-11-06 2002-11-05 Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor ATE352319T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17

Publications (1)

Publication Number Publication Date
ATE352319T1 true ATE352319T1 (de) 2007-02-15

Family

ID=26988512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787572T ATE352319T1 (de) 2001-11-06 2002-11-05 Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor

Country Status (22)

Country Link
US (3) US7402603B2 (de)
EP (1) EP1443967B1 (de)
JP (1) JP4413614B2 (de)
KR (1) KR100937064B1 (de)
CN (1) CN100457183C (de)
AT (1) ATE352319T1 (de)
AU (1) AU2002351844B2 (de)
BR (1) BR0213932A (de)
CA (1) CA2461373A1 (de)
CY (1) CY1106508T1 (de)
DE (1) DE60217895T2 (de)
DK (1) DK1443967T3 (de)
ES (1) ES2280597T3 (de)
HU (1) HUP0402370A3 (de)
IL (2) IL160970A0 (de)
MX (1) MXPA04004312A (de)
NO (1) NO20042148L (de)
NZ (1) NZ544689A (de)
PL (1) PL205853B1 (de)
PT (1) PT1443967E (de)
RU (1) RU2311200C2 (de)
WO (1) WO2003039599A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
MXPA05012464A (es) * 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
AU2005272389B2 (en) * 2004-08-11 2011-08-04 Kyorin Pharmaceutical Co., Ltd. Novel cyclic aminobenzoic acid derivative
EP1824831A2 (de) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
EP1896436A2 (de) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
EP1743654A1 (de) * 2005-07-15 2007-01-17 TopoTarget Germany AG Verwendung von Histon Deacetylase-Hemmer zusammen mit NSAIDen zur Behandlung von Krebs und/oder Entzündungskrankheiten
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2007146718A2 (en) 2006-06-12 2007-12-21 Novartis Ag Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino] methyl]phenyl]-2e-2-propenamide and starting materials therefor
ME00529B (me) * 2006-06-12 2011-10-10 Novartis Ag Polimorfi n-hidroksi-3-[4-[[[2-(-metil-1h-indol-3-il)etil]amino]fenil]-2e-2-propenamida
RU2008151724A (ru) * 2006-06-12 2010-07-20 Новартис АГ (CH) Способ получения солей n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
MX2008016503A (es) * 2006-06-28 2009-06-08 Novartis Ag Uso de inhibidores de hdac para el tratamiento de linfomas.
EP2055692A4 (de) * 2006-08-25 2010-07-07 Asahi Glass Co Ltd Verfahren zur herstellung von 1,2-dialkoxy-3-fluorbenzol
CA2676422C (en) 2007-02-06 2018-10-16 Lixte Biotechnology Holdings, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US20100069458A1 (en) * 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
EA018618B1 (ru) 2007-10-01 2013-09-30 Ликсте Байотекнолоджи, Инк. Ингибиторы hdac
CA2730148C (en) 2008-08-01 2018-04-03 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
KR20140144696A (ko) * 2012-04-16 2014-12-19 도아 에이요 가부시키가이샤 ２환성 화합물
EP2983661B1 (de) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulierungen von oxabicycloheptanen und oxabicycloheptenen
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
MX2019006694A (es) 2016-12-08 2019-08-21 Lixte Biotechnology Inc Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
JP2005510517A (ja) 2005-04-21
WO2003039599A1 (en) 2003-05-15
CA2461373A1 (en) 2003-05-15
PT1443967E (pt) 2007-04-30
AU2002351844B2 (en) 2006-12-21
DE60217895T2 (de) 2007-07-05
MXPA04004312A (es) 2005-05-16
US20090192211A1 (en) 2009-07-30
KR20050043744A (ko) 2005-05-11
US7402603B2 (en) 2008-07-22
US20050032899A1 (en) 2005-02-10
RU2311200C2 (ru) 2007-11-27
PL205853B1 (pl) 2010-06-30
IL160970A0 (en) 2004-08-31
RU2004117170A (ru) 2005-04-20
BR0213932A (pt) 2004-08-31
HUP0402370A2 (hu) 2005-02-28
CY1106508T1 (el) 2012-01-25
DK1443967T3 (da) 2007-04-16
JP4413614B2 (ja) 2010-02-10
HUP0402370A3 (en) 2008-04-28
NZ544689A (en) 2007-08-31
CN100457183C (zh) 2009-02-04
PL368539A1 (en) 2005-04-04
CN1578674A (zh) 2005-02-09
IL160970A (en) 2010-06-30
KR100937064B1 (ko) 2010-01-15
EP1443967A1 (de) 2004-08-11
ES2280597T3 (es) 2007-09-16
NO20042148L (no) 2004-08-04
DE60217895D1 (en) 2007-03-15
US20080227845A1 (en) 2008-09-18
EP1443967B1 (de) 2007-01-24

Similar Documents

Publication Publication Date Title
ATE352319T1 (de) Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
MXPA05012464A (es) Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
BR9914044A (pt) ésteres tetrahidropirido
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
ATE408601T1 (de) Fredericamycin-derivate
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
JO2434B1 (en) New retinoids to treat emphysema
DE60233261D1 (de) Inhibitoren von humanem adam-10
BRPI0408466A (pt) composições farmacêuticas de inibidores de cetp e uso dos referidos inibidores
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
ATE345790T1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
WO2007024574A3 (en) Topical formulations of histone deacetylase inhibitors and methods of using the same
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases
ATE453614T1 (de) Sphingolipiden
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DE602004008247D1 (de) Zusammensetzung die tamsulosin und ein nichtsteroides entzündungshemmendes mittel enthält
BR0212607A (pt) Agonistas retinóides ii de uréia substituìda
SI1594456T1 (sl) Uporaba zmesi, ki vsebuje oksid vitamina k1 ali njegov derivat, pri zdravljenju in/ali preprečevanju dermatoloških lezij pri sesalcih
ECSP045071A (es) Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de desacetilasa de histona

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1443967

Country of ref document: EP